July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Future Therapies for Fuchs Endothelial Corneal Dystrophy
Author Affiliations & Notes
  • Ula V. Jurkunas
    Ophthalmology/Harvard Med Sch, MA Eye & Ear Infirm Schepens Eye Res, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Ula Jurkunas, Intelia (F), Mitobridge (C), Stealth (C), US Patent (P), Wave Life Sciences (C)
  • Footnotes
    Support  NH Grant EY020581
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3917. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ula V. Jurkunas; Future Therapies for Fuchs Endothelial Corneal Dystrophy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3917.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : The presentation will outline how endogenous and exogenous oxidative stress combined with genetic factors and cellular post-mitotic arrest leads to endothelial cell loss in Fuchs endothelial corneal dystrophy.In addition it will show that chronic accumulation of oxidative DNA damage contributes to the corneal endothelial cell degeneration by causing loss of mitochondrial membrane potential, mitochondrial fragmentation and apoptosis in FECD. Therefore, therapies targetting aging and oxidative stress pathways could provide alternatives to corneal transpantation for FECD patients. Morover, lifestyle and environmental modifications could be applied to Fuchs patients, similarly to what is being done for other age-related ocular disorders.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.